Skip to content

Marissa Raymond-Flesch

University of California San Francisco, Department of Pediatrics, 550 16th St. Box 0110, San Francisco, CA 94143, USA; University of California San Francisco, Philip R. Lee Institute for Health Policy Studies, USA.

4 papers in the library · 40 citations · publishing 2024-2026

Papers

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.

Psychiatry research March 1, 2025 Stephanie L Haft, Amanda E Downey, Marissa Raymond-Flesch et al. 22 citations

A systematic review of 21 randomized controlled trials of psilocybin- and MDMA-assisted therapies (total 1034 participants) found that participant samples lack diversity. Gender was always reported, race or ethnicity in 76% of trials, and socioeconomic status in 57%. Sexual orientation (9.5%) and immigration status (4.8%) were rarely reported; no study reported gender identity. Compared to the US population and non-psychedelic clinical trials, Black/African-American participants (2.2%) and Hispanic/Latino participants (7.2%) were significantly underrepresented. MDMA trials enrolled more diverse samples than psilocybin trials. Analyses of treatment effects by demographic variables were virtually absent. The findings indicate a need for inclusive recruitment and rigorous reporting to improve generalizability.

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.

Journal of eating disorders April 24, 2024 Amanda E Downey, Anita V Chaphekar, Joshua Woolley et al. 13 citations

Clinical trials are testing psilocybin therapy for anorexia nervosa (AN), but individuals with AN have unique medical vulnerabilities. This review describes how common physiologic adverse effects of psilocybin—tachycardia, hypertension, electrocardiogram changes, nausea, headache, and lightheadedness—may interact with medical complications seen in AN. It proposes risk mitigation strategies for each adverse effect. Early evidence suggests psilocybin therapy is well-tolerated in individuals with AN. Understanding AN's medical complications in relation to psilocybin's effects can help tailor strategies to enhance safety and tolerability of this novel intervention.

Leveraging family and caregiver support in psychedelic-assisted therapy: considerations for the treatment of adolescents.

Child and adolescent psychiatry and mental health June 4, 2025 Sarah Forsberg, Amanda E Downey, Lindsey D Bruett et al. 5 citations

Psychedelic-assisted therapy is gaining interest for treating mental health conditions in adolescents, but safe and effective delivery requires careful consideration of caregiver involvement. Caregivers are essential in adolescent mental health treatment, supporting recovery and disrupting illness-maintaining patterns, while also needing resources to manage caregiving challenges. This review synthesizes evidence from adolescent mental health treatments, PAT best practices, and family systems theory to propose a framework for integrating caregivers into adolescent PAT. The family system is a critical setting that may shape PAT efficacy, analogous to the therapeutic setting (set and setting). Recommendations are provided for incorporating caregivers into PAT protocols to maximize safety and efficacy.

Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care.

Current psychiatry reports May 14, 2026 Jamarie A Geller, Rachel Pacilio, Amanda E Downey et al.

Psilocybin-assisted therapy may hold promise for anorexia nervosa, a serious and often treatment-resistant illness. Although research has focused on adults, anorexia frequently begins in adolescence, and early onset is linked to more severe illness, greater psychiatric comorbidity, and more life difficulties. The authors argue that exploring the theoretical potential of this therapy for adolescents is warranted, considering biological implications, developmental stage, and consent. They propose adaptations to adult treatment models and discuss emerging models that address the unique challenges of adolescent patients.